Envestnet Asset Management
AIMT

Envestnet Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Envestnet Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-35,141
Closed -$587K – 3234
2020
Q2 		$587K Buy
35,141
+304
+0.9% +$5.16K ﹤0.01% 2319
2020
Q1 		$502K Sell
34,837
-12,328
-26% -$315K ﹤0.01% 2231
2019
Q4 		$1.58M Buy
47,165
+21,388
+83% +$598K ﹤0.01% 1753
2019
Q3 		$540K Buy
+25,777
New +$526K ﹤0.01% 2329
2018
Q3 		– Sell
-1,437
Closed -$39K – 2933
2018
Q2 		$39K Buy
1,437
+15
+1% +$459 ﹤0.01% 2279
2018
Q1 		$45K Sell
1,422
-70
-5% -$2.46K ﹤0.01% 2181
2017
Q4 		$56K Buy
1,492
+152
+11% +$4.91K ﹤0.01% 2293
2017
Q3 		$33K Buy
1,340
+73
+6% +$1.57K ﹤0.01% 2400
2017
Q2 		$26K Sell
1,267
-21
-2% -$401 ﹤0.01% 2544
2017
Q1 		$28K Sell
1,288
-2
-0.2% -$41 ﹤0.01% 2599
2016
Q4 		$26K Buy
1,290
+149
+13% +$3.05K ﹤0.01% 2609
2016
Q3 		$17K Sell
1,141
-114
-9% -$1.54K ﹤0.01% 2833
2016
Q2 		$14K Sell
1,255
-274
-18% -$3.72K ﹤0.01% 3011
2016
Q1 		$21K Buy
+1,529
New +$23.9K ﹤0.01% 2957

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Envestnet Asset Management's AIMT Position: Q3 2020 in Review

Envestnet Asset Management sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 35,141 shares — an estimated $587K sold.

Envestnet Asset Management first reported a position in AIMT in Q1 2016 and held it in 14 quarters. The position peaked at $1.58M in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Envestnet Asset Management reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Envestnet Asset Management sold 35,141 Aimmune Therapeutics shares in Q3 2020, an estimated $587K.
  • Envestnet Asset Management first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 14 quarters.
  • Envestnet Asset Management's Aimmune Therapeutics position peaked at $1.58M in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Envestnet Asset Management's 13F filing for Q3 2020, filed 9 Oct 2020.